A human synthetic peptide-based influenza vaccine for intranasaladministration comprises a mixture of flagella containing at least fourepitopes of influenza virus reactive with human cells, each expressedindividually in Salmonella flagellin, said influenza virus epitopes beingselected from the group consisting of: (i) one B-cell hemagglutinin (HA)epitope； (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitopethat can bind to many HLA molecules； and (iii) at least two cytotoxiclymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that arerestricted to the most prevalent HLA molecules in different human populations.
